FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987443556> ?p ?o ?g. }

• W1987443556 endingPage "13" @default.
• W1987443556 startingPage "13" @default.
• W1987443556 abstract "An overwhelming amount of experimental and observational information about the basic processes underlying carcinogenesis obtained during the 1970s to 1990s, led to a series of translational and eventually definitive placebo-controlled, double blind randomized controlled trials (RCT), involving patients at increased risk for breast, prostate, non-melanoma skin, cervix, chronic myelogenous leukemia (CML), and colon cancer. Despite clear evidence of the favorable effects on the primary endpoints, regulatory approval has been low and usage of those compounds, which have been approved, has been minimal to non-existent. How come? And what can we do to improve this situation, as we move ahead to the next generation of clinical studies?For cervical cancer and CML, respectively, we have the good news that a highly effective vaccine and a targeted therapy (Imatinib) supplanted retinoids as the intervention of choice.[1,2] However, it is probably still worth looking into the vitamin A status of patients who develop cervical cancer, who have received the vaccine, or CML patients who relapse on Imatinib.For the remaining malignancies the issues are very similar. We have recently presented a comprehensive review of this topic, including for those interested, a discussion of regulatory and business challenges.[3] In this current perspective we will focus on the issues of particular concern to the audience being served at this symposium: Scientific, translational, and clinical issues related to colorectal cancer.The major questions that need to be asked and addressed regardless of the organ site are contained in these five areas:What relevance do cellular, animal studies, and epidemiological observations have to the cancer in ‘at-risk individuals′?How can we better identify those at true risk, to develop a more favorable risk-benefit profile?How can we better assess toxicity, and thus a potential risk-benefit in our preclinical experiments?How can we better convey the risks and benefits to trial participants in prevention studies? to regulatory bodies (FDA, EMA, etc.) after a positive RCT? or to potential future patients after a drug is approved?How should we move forward?" @default.
• W1987443556 created "2016-06-24" @default.
• W1987443556 creator A5060872059 @default.
• W1987443556 date "2011-01-01" @default.
• W1987443556 modified "2023-10-17" @default.
• W1987443556 title "Therapeutic prevention of colorectal carcinogenesis" @default.
• W1987443556 cites W139819387 @default.
• W1987443556 cites W1971540249 @default.
• W1987443556 cites W1982248155 @default.
• W1987443556 cites W1988783822 @default.
• W1987443556 cites W2004916700 @default.
• W1987443556 cites W2006464072 @default.
• W1987443556 cites W2010899039 @default.
• W1987443556 cites W2012603529 @default.
• W1987443556 cites W2033624890 @default.
• W1987443556 cites W2068978328 @default.
• W1987443556 cites W2097235831 @default.
• W1987443556 cites W2149677280 @default.
• W1987443556 cites W2319872820 @default.
• W1987443556 cites W2329648702 @default.
• W1987443556 cites W2336215030 @default.
• W1987443556 doi "https://doi.org/10.4103/1477-3163.79682" @default.
• W1987443556 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3122104" @default.
• W1987443556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21712960" @default.
• W1987443556 hasPublicationYear "2011" @default.
• W1987443556 type Work @default.
• W1987443556 sameAs 1987443556 @default.
• W1987443556 citedByCount "1" @default.
• W1987443556 countsByYear W19874435562012 @default.
• W1987443556 crossrefType "journal-article" @default.
• W1987443556 hasAuthorship W1987443556A5060872059 @default.
• W1987443556 hasBestOaLocation W19874435561 @default.
• W1987443556 hasConcept C121608353 @default.
• W1987443556 hasConcept C126322002 @default.
• W1987443556 hasConcept C143998085 @default.
• W1987443556 hasConcept C502942594 @default.
• W1987443556 hasConcept C526805850 @default.
• W1987443556 hasConcept C555283112 @default.
• W1987443556 hasConcept C71924100 @default.
• W1987443556 hasConceptScore W1987443556C121608353 @default.
• W1987443556 hasConceptScore W1987443556C126322002 @default.
• W1987443556 hasConceptScore W1987443556C143998085 @default.
• W1987443556 hasConceptScore W1987443556C502942594 @default.
• W1987443556 hasConceptScore W1987443556C526805850 @default.
• W1987443556 hasConceptScore W1987443556C555283112 @default.
• W1987443556 hasConceptScore W1987443556C71924100 @default.
• W1987443556 hasIssue "1" @default.
• W1987443556 hasLocation W19874435561 @default.
• W1987443556 hasLocation W19874435562 @default.
• W1987443556 hasLocation W19874435563 @default.
• W1987443556 hasLocation W19874435564 @default.
• W1987443556 hasLocation W19874435565 @default.
• W1987443556 hasLocation W19874435566 @default.
• W1987443556 hasOpenAccess W1987443556 @default.
• W1987443556 hasPrimaryLocation W19874435561 @default.
• W1987443556 hasRelatedWork W1506200166 @default.
• W1987443556 hasRelatedWork W1995515455 @default.
• W1987443556 hasRelatedWork W2048182022 @default.
• W1987443556 hasRelatedWork W2080531066 @default.
• W1987443556 hasRelatedWork W2604872355 @default.
• W1987443556 hasRelatedWork W2748952813 @default.
• W1987443556 hasRelatedWork W2899084033 @default.
• W1987443556 hasRelatedWork W3031052312 @default.
• W1987443556 hasRelatedWork W3032375762 @default.
• W1987443556 hasRelatedWork W3108674512 @default.
• W1987443556 hasVolume "10" @default.
• W1987443556 isParatext "false" @default.
• W1987443556 isRetracted "false" @default.
• W1987443556 magId "1987443556" @default.
• W1987443556 workType "article" @default.